๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma

โœ Scribed by Berghmans, T.; Lafitte, J.J.; Paesmans, M.; Stach, B.; Berchier, M.C.; Wackenier, P.; Lecomte, J.; Collon, T.; Mommen, P.; Sculier, J.P.

Book ID
119319237
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
182 KB
Volume
50
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

A phase II study of VP-16 and cisplatin
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma
โœ Elizabeth A. Eisenhauer; William K. Evans; Nevin Murray; Walter Kocha; Rafal Wie ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 204 KB

The National Cancer Institute of Canada (NCIC) Clinical Trials Group has carried out a phase II study of VP-16 100 mg/m 2 daily x 3 and cisplatin 25 mg/m 2 daily x 3 in untreated patients with malignant mesothelioma. Twenty-seven eligible patients were entered on the trial and the majority had pleur

Gemcitabine combined with carboplatin in
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma : A multicentric Phase II study
โœ Adolfo G. Favaretto; Savina M. L. Aversa; Adriano Paccagnella; Vincenzo De Pangh ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 90 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Malignant pleural mesothelioma (MPM) is increasing rapidly worldwide. Currently, pemetrexed plus cisplatin chemotherapy showed a survival advantage versus cisplatin alone. No impact on patient survival of surgery, radiotherapy, or their combination has been demonstrated.

A phase II evaluation of cisplatin in un
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
โœ Bernard L. Zidar; Stephanie Green; H. I. Pierce; Ralph W. Roach; Stanley P. Balc ๐Ÿ“‚ Article ๐Ÿ“… 1988 ๐Ÿ› Springer US ๐ŸŒ English โš– 240 KB

Cisplatin was given intravenously to 35 evaluable patients with unresectable malignant mesothelioma on Southwest Oncology Group (SWOG) Study 8418. Five patients (14.3%) achieved partial response with median response duration of six months (range 2-12 months); eleven patients (31.4%) had stable disea